Advertisement
ABBV vs JNJ
Which Stock Would AI Choose? AbbVie (ABBV) vs. Johnson & Johnson (JNJ) Stock Comparison
Key Takeaways
- ABBV has delivered double-digit revenue growth in recent quarters, driven by strong performance in its immunology portfolio including Skyrizi and Rinvoq.
- JNJ maintains a diversified business across innovative medicines and MedTech, supporting more stable revenue streams compared to the concentrated exposure in ABBV.
- Recent market activity shows ABBV benefiting from pipeline advancements and an acquisition, while JNJ has reported positive clinical data in oncology.
- Valuation metrics indicate ABBV trades at a higher trailing price-to-earnings ratio than JNJ, reflecting differences in growth profiles and profitability margins.
- Both stocks operate in the healthcare sector with defensive characteristics, though JNJ offers broader exposure across pharmaceuticals and medical devices.
- Sentiment in recent weeks has been supported by clinical trial successes for both companies, with relative performance varying by timeframe.
Introduction
Investors and traders often compare ABBV and JNJ as leading healthcare equities with established dividend histories and exposure to pharmaceutical innovation. This analysis examines their business models, recent performance trends, and market positioning in the current environment. The comparison is particularly relevant for those seeking defensive sector exposure, dividend income, or insights into relative momentum within large-cap healthcare. Data draws from publicly available financial reports and market observations to highlight contrasts in growth drivers and risk profiles.
AbbVie Overview and Recent Performance
AbbVie Inc. focuses primarily on immunology, oncology, and neuroscience therapies. In recent market activity, the stock has shown resilience amid positive clinical developments and corporate actions. The company reported robust second-quarter revenue growth, fueled by double-digit increases in key products such as Skyrizi and Rinvoq. Recent weeks featured the completion of a significant acquisition expanding its immunology pipeline and favorable Phase 3 results for a migraine treatment candidate. These factors have contributed to upward revisions in revenue guidance and supported sentiment. The stock has exhibited moderate volatility with gains over the past month, reflecting investor focus on pipeline execution.
Johnson & Johnson Overview and Recent Performance
Johnson & Johnson operates across innovative medicines and MedTech segments, providing diversified revenue sources. Recent market activity has highlighted clinical progress in oncology and regulatory milestones in vision care. The company has maintained steady operational performance with consistent contributions from its pharmaceutical and device portfolios. In recent weeks, positive data readouts for lung cancer therapies and new product approvals in Europe have bolstered visibility. The stock has demonstrated relative stability compared to more concentrated peers, with performance supported by broader healthcare sector dynamics. Overall positioning reflects a balance of established franchises and ongoing pipeline investments.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases a curated selection of AI trading bots optimized for prevailing market conditions. Tickeron offers hundreds of AI Trading Bots that trade thousands of different tickers across equities, with only the highest-performing and most suitable ones featured in the trending section based on backtested statistics, live performance, and adaptability. Available bots span a wide range of trading styles, strategies, timeframes, risk parameters, and ticker sets, with performance metrics such as win rates, profit factors, and drawdown statistics varying by bot. This diversity allows users to explore options aligned with specific objectives. Review the full selection on the Trending AI Robots page for detailed analytics and deployment considerations.
Head-to-Head Comparison
ABBV operates with a more focused business model centered on high-growth immunology assets, leading to higher revenue growth rates in recent periods but also greater concentration risk. In contrast, JNJ benefits from diversification across pharmaceuticals and MedTech, which supports steadier cash flows and lower earnings volatility. Recent momentum has favored ABBV on acquisition-related catalysts, while JNJ has shown strength in broader clinical updates. Risk factors for ABBV include patent exposures and integration of new assets, whereas JNJ faces ongoing litigation and regulatory considerations across segments. Sector exposure is similar, though JNJ’s MedTech component provides additional ballast during pharmaceutical-specific shifts. Market sentiment remains constructive for both, with relative outperformance tied to individual catalysts.
Tickeron AI Verdict
Based on observable factors such as trend consistency in recent market activity, pipeline stability, and relative positioning within the healthcare sector, Tickeron’s AI would currently assign a probabilistic preference toward JNJ for its diversified revenue base and demonstrated resilience. ABBV shows competitive momentum from recent developments but carries higher concentration in specific therapeutic areas. This assessment reflects pattern recognition across available data rather than definitive forecasts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABBV is a Hold and JNJ is a Hold.
| ABBV | JNJ | ABBV / JNJ | |
| Capitalization | 464B | 644B | 72% |
| EBITDA | 19.5B | 34B | 57% |
| Gain YTD | 18.255 | 32.560 | 56% |
| P/E Ratio | 74.58 | 31.35 | 238% |
| Revenue | 64.4B | 97.9B | 66% |
| Total Cash | 6.57B | 20.8B | 32% |
| Total Debt | 70.8B | 49B | 144% |
ABBV | JNJ | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 28 | 86 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 16 Undervalued | 12 Undervalued | |
PROFIT vs RISK RATING 1..100 | 5 | 5 | |
SMR RATING 1..100 | 1 | 37 | |
PRICE GROWTH RATING 1..100 | 25 | 23 | |
P/E GROWTH RATING 1..100 | 78 | 10 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
JNJ's Valuation (12) in the Pharmaceuticals Major industry is in the same range as ABBV (16). This means that JNJ’s stock grew similarly to ABBV’s over the last 12 months.
JNJ's Profit vs Risk Rating (5) in the Pharmaceuticals Major industry is in the same range as ABBV (5). This means that JNJ’s stock grew similarly to ABBV’s over the last 12 months.
ABBV's SMR Rating (1) in the Pharmaceuticals Major industry is somewhat better than the same rating for JNJ (37). This means that ABBV’s stock grew somewhat faster than JNJ’s over the last 12 months.
JNJ's Price Growth Rating (23) in the Pharmaceuticals Major industry is in the same range as ABBV (25). This means that JNJ’s stock grew similarly to ABBV’s over the last 12 months.
JNJ's P/E Growth Rating (10) in the Pharmaceuticals Major industry is significantly better than the same rating for ABBV (78). This means that JNJ’s stock grew significantly faster than ABBV’s over the last 12 months.
| ABBV | JNJ | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 49% | 2 days ago 34% |
| Stochastic ODDS (%) | 1 day ago 46% | 2 days ago 58% |
| Momentum ODDS (%) | 1 day ago 64% | 2 days ago 47% |
| MACD ODDS (%) | 1 day ago 61% | 2 days ago 32% |
| TrendWeek ODDS (%) | 1 day ago 64% | 2 days ago 47% |
| TrendMonth ODDS (%) | 1 day ago 65% | 2 days ago 51% |
| Advances ODDS (%) | 4 days ago 61% | 2 days ago 47% |
| Declines ODDS (%) | 11 days ago 46% | 8 days ago 40% |
| BollingerBands ODDS (%) | 1 day ago 63% | 2 days ago 35% |
| Aroon ODDS (%) | N/A | 2 days ago 50% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABBV’s FA Score shows that 4 FA rating(s) are green while JNJ’s FA Score has 4 green FA rating(s).
- ABBV’s FA Score: 4 green, 1 red.
- JNJ’s FA Score: 4 green, 1 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABBV’s TA Score shows that 5 TA indicator(s) are bullish while JNJ’s TA Score has 3 bullish TA indicator(s).
- ABBV’s TA Score: 5 bullish, 3 bearish.
- JNJ’s TA Score: 3 bullish, 5 bearish.
Price Growth
ABBV (@Pharmaceuticals: Major) experienced а +2.66% price change this week, while JNJ (@Pharmaceuticals: Major) price change was +1.66% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.82%. For the same industry, the average monthly price growth was -6.21%, and the average quarterly price growth was +15.37%.
Reported Earning Dates
ABBV is expected to report earnings on Oct 23, 2026.
JNJ is expected to report earnings on Oct 20, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (+1.82% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
ABBV and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABBV has been loosely correlated with BMY. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ABBV jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To ABBV | 1D Price Change % | ||
|---|---|---|---|---|
| ABBV | 100% | -0.02% | ||
| BMY - ABBV | 51% Loosely correlated | +0.35% | ||
| NVS - ABBV | 50% Loosely correlated | -0.39% | ||
| JNJ - ABBV | 49% Loosely correlated | -0.09% | ||
| MRK - ABBV | 46% Loosely correlated | -0.19% | ||
| AMGN - ABBV | 46% Loosely correlated | +1.55% | ||
More | ||||
JNJ and
Correlation & Price change
A.I.dvisor indicates that over the last year, JNJ has been loosely correlated with PFE. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if JNJ jumps, then PFE could also see price increases.